These encouraging
preclinical results suggest the compound, known as GS - 5734, should be further developed as a potential treatment, according to research findings to be presented tomorrow at the IDWeek conference.
Not exact matches
The
results suggest that worsening anxious - depressive symptoms may be an early predictor of elevated amyloid beta levels — and, in turn AD — and provide support for the hypothesis that emerging neuropsychiatric symptoms represent an early manifestation of
preclinical Alzheimer's disease.
SMA researchers then presented
results from
preclinical models that
suggest SMA is a whole - body disease.
These
results are consistent with emerging
preclinical and clinical data
suggesting that the negative sequelae associated with early stress are not inevitable.